LifeVantage Corporation reports developments for a health and wellness company built around nutrigenomics, dietary supplements, skin and hair care products, nootropic energy drink mixes, and pet supplements. Its product line includes Protandim, TrueScience Liquid Collagen, MindBody GLP-1 System, LoveBiome P84, AXIO, TrueScience skin and hair care products, and Petandim, sold through independent Consultants to customers.
Company news commonly covers quarterly results, regional sales trends, product innovation, patents tied to cellular-signaling supplement compositions, consultant events and training, international market expansion, executive leadership changes, share repurchases, and cash dividends. Updates also describe capital allocation and the company’s direct-selling business model.
LifeVantage (Nasdaq: LFVN) has declared a quarterly cash dividend payable December 15, 2026, to common stockholders. The board approved a payment of $0.050 per share to stockholders of record at the close of business on December 1, 2026.
LifeVantage (Nasdaq: LFVN) reported fiscal first-quarter 2027 revenue of $37.1 million, down from the same quarter a year earlier. Revenue fell 22.0% in the quarter ended September 30, 2026. Americas revenue declined 22.2%, while Asia/Pacific & Europe revenue decreased 21.2%. Net loss was $0.2 million, or $0.02 per diluted share, versus net income of $2.2 million, or $0.17 per diluted share.
Gross margin fell to 75.4% from 79.5%, reflecting a MindBody inventory allowance and higher shipping and warehouse expenses. Adjusted earnings per diluted share declined to $0.05 from $0.18, and adjusted EBITDA fell to $1.9 million from $3.9 million. Operating cash flow turned positive at $0.5 million, versus $2.3 million used a year earlier. Cash totaled $13.7 million, down from $14.9 million at June 30, 2026, with no debt outstanding.
LifeVantage (LFVN) reported laboratory research examining Protandim Nrf2 and cellular responses to five categories of environmental toxins in controlled conditions. The study tested liver, skin/connective-tissue and intestinal-lining cells, comparing unexposed cells with cells exposed to toxins alone or toxins plus Protandim Nrf2.
Across all five categories, treated cells showed significantly lower oxidative stress signals than cells exposed to toxins alone; some signals were comparable to unexposed cells. These are cell-study findings, not evidence that the product removes toxins or prevents exposure. LifeVantage also launched Cell Care, an educational campaign with a quiz about habits and potential exposures.
LifeVantage (LFVN) will announce its first-quarter fiscal 2027 financial results after the stock market closes on November 9, 2026. The quarter ended September 30, 2026. An investor conference call will follow that day at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time), with a simultaneous live webcast available through the company’s Investor Relations website.
LifeVantage (LFVN) granted stock-based inducement awards to President and CEO Terrence Moorehead on October 7, 2026, under its new-employee incentive plan.
The awards include 128,824 restricted stock units, vesting in three equal annual installments beginning one year after grant. Performance-based units represent 193,237 shares at target, or up to 289,855 shares at maximum performance, tied to revenue and Adjusted EBITDA margin targets over 3.5 years. Both awards require continued service through applicable vesting dates. The grants implement an executive benefits agreement dated April 15, 2026, under Nasdaq Listing Rule 5635(c)(4).
LifeVantage (LFVN)/b) will participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026.Chief Executive Officer Terrence Moorehead and Chief Financial Officer Carl Aure will present at the event, with a webcast starting at approximately 1:30 p.m. Eastern Time on the same day. The conference is open to all investors, who can access registration via the company’s Investor Relations website.
LifeVantage (Nasdaq: LFVN) reported fourth quarter fiscal 2026 revenue of $42.4 million, down 23.1% year over year, with Americas revenue down 24.8% and Asia/Pacific & Europe down 16.9%. Q4 diluted EPS was $0.10 versus $0.15, and adjusted EPS was $0.11 versus $0.17. Adjusted EBITDA was $2.7 million, down from $4.8 million.
For fiscal 2026, revenue was $182.6 million, a 20.1% decline from 2025, and diluted EPS was $0.40 versus $0.75. Adjusted EPS was $0.56 versus $0.82, and adjusted EBITDA fell to $13.7 million from $22.1 million. Gross margin was 77.6% versus 80.4%, pressured by an inventory obsolescence allowance and product mix, including lower MindBody GLP-1 System sales, partially offset by LoveBiome. The company ended June 30, 2026 with $14.9 million in cash, no debt, generated $10.2 million in operating cash flow, repurchased 336,000 shares for about $2.0 million, and did not issue fiscal 2027 guidance following a CEO transition.
LifeVantage (Nasdaq: LFVN) announced that its Board of Directors has approved a quarterly cash dividend of $0.050 per share of common stock. The dividend is scheduled to be paid on September 15, 2026 to stockholders of record as of the close of business on September 1, 2026.
LifeVantage (Nasdaq: LFVN) will release its fourth quarter and full fiscal year 2026 financial results, for the period ended June 30, 2026, after the market close on Thursday, August 27, 2026.
The company will host an investor conference call at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) the same day, with U.S. access at (877) 704-4453 and international access at (201) 389-0920. A telephone replay will be available until September 17, 2026 using confirmation code 13761673, and a live webcast plus a 30-day archive will be accessible via the LifeVantage investor relations website or directly through the provided webcast link.
LifeVantage (Nasdaq: LFVN) announced that its Board granted inducement equity awards to new President and CEO Terrence Moorehead under the 2026 New Employee Long-Term Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted on August 6, 2026.
The package includes 308,642 RSUs, vesting in three equal annual installments starting one year from grant, and 540,123 performance-based RSUs that may vest over three years based on revenue and Adjusted EBITDA margin targets, in each case subject to Mr. Moorehead’s continued service.